David Egging

1.1k total citations
22 papers, 723 citations indexed

About

David Egging is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Genetics. According to data from OpenAlex, David Egging has authored 22 papers receiving a total of 723 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Radiology, Nuclear Medicine and Imaging, 7 papers in Oncology and 7 papers in Genetics. Recurrent topics in David Egging's work include Monoclonal and Polyclonal Antibodies Research (11 papers), Connective tissue disorders research (7 papers) and HER2/EGFR in Cancer Research (7 papers). David Egging is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (11 papers), Connective tissue disorders research (7 papers) and HER2/EGFR in Cancer Research (7 papers). David Egging collaborates with scholars based in Netherlands, United States and United Kingdom. David Egging's co-authors include Joost Schalkwijk, Wim H.A. Dokter, Ruud Ubink, Gijs Verheijden, Patrick H. Beusker, Miranda M.C. van der Lee, Jacques Lemmens, William A. Carey, James Bristow and A. C. T. M. Peeters and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Protein Science.

In The Last Decade

David Egging

22 papers receiving 695 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Egging Netherlands 14 322 312 234 152 96 22 723
Fiorella Petronzelli Italy 18 200 0.6× 252 0.8× 480 2.1× 177 1.2× 49 0.5× 41 1.2k
M. I. Colnaghi Italy 15 402 1.2× 585 1.9× 487 2.1× 76 0.5× 71 0.7× 26 1.1k
Heli Valtanen Finland 8 119 0.4× 492 1.6× 449 1.9× 48 0.3× 226 2.4× 9 1.0k
Laurence Maggiorella France 11 81 0.3× 291 0.9× 340 1.5× 45 0.3× 35 0.4× 17 793
Bernard M. Tijink Netherlands 12 540 1.7× 424 1.4× 333 1.4× 19 0.1× 74 0.8× 24 1.1k
Camilla Fröhlich Denmark 17 92 0.3× 477 1.5× 466 2.0× 80 0.5× 282 2.9× 22 1.1k
Merel Gijsen United Kingdom 9 222 0.7× 364 1.2× 212 0.9× 21 0.1× 50 0.5× 17 540
Hidekazu Segawa Japan 15 180 0.6× 458 1.5× 317 1.4× 36 0.2× 13 0.1× 20 985
E. Kutarska Poland 12 200 0.6× 440 1.4× 274 1.2× 55 0.4× 8 0.1× 17 939
FO Smith United States 9 189 0.6× 281 0.9× 426 1.8× 40 0.3× 37 0.4× 15 1.1k

Countries citing papers authored by David Egging

Since Specialization
Citations

This map shows the geographic impact of David Egging's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Egging with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Egging more than expected).

Fields of papers citing papers by David Egging

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Egging. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Egging. The network helps show where David Egging may publish in the future.

Co-authorship network of co-authors of David Egging

This figure shows the co-authorship network connecting the top 25 collaborators of David Egging. A scholar is included among the top collaborators of David Egging based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Egging. David Egging is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ubink, Ruud, Ebo Bos, I. Janssen, et al.. (2018). Unraveling the Interaction between Carboxylesterase 1c and the Antibody–Drug Conjugate SYD985: Improved Translational PK/PD by Using Ces1c Knockout Mice. Molecular Cancer Therapeutics. 17(11). 2389–2398. 28 indexed citations
2.
Egging, David, et al.. (2018). Sensitivity and Drug Tolerance of Antidrug Antibody Assays in Relation to Positive Control Characteristics. Bioanalysis. 10(16). 1289–1306. 8 indexed citations
3.
Goodman, Joanne, Simon Cowen, Viswanath Devanarayan, et al.. (2018). Feedback from the European Bioanalysis Forum: Focus Workshop on Current Analysis of Immunogenicity: Best Practices and Regulatory Hurdles. Bioanalysis. 10(4). 197–204. 9 indexed citations
4.
Egging, David, et al.. (2017). Rapid screening of IgG quality attributes – effects on Fc receptor binding. FEBS Open Bio. 7(10). 1557–1574. 22 indexed citations
5.
Egging, David, et al.. (2017). Rapid Buffer and Ligand Screening for Affinity Chromatography by Multiplexed Surface Plasmon Resonance Imaging. Biotechnology Journal. 12(9). 5 indexed citations
6.
Selmaj, Krzysztof, Frederik Barkhof, Christian Wolf, et al.. (2017). Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results. Multiple Sclerosis Journal. 23(14). 1909–1917. 19 indexed citations
7.
8.
Rouwendal, Gerard, Saskia Meyer, Karli R. Reiding, et al.. (2015). A comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA. mAbs. 8(1). 74–86. 41 indexed citations
9.
Elgersma, Ronald C., Ruud G. E. Coumans, Wiro M. P. B. Menge, et al.. (2015). Design, Synthesis, and Evaluation of Linker-Duocarmycin Payloads: Toward Selection of HER2-Targeting Antibody–Drug Conjugate SYD985. Molecular Pharmaceutics. 12(6). 1813–1835. 163 indexed citations
10.
Lee, Miranda M.C. van der, Patrick G. Groothuis, Ruud Ubink, et al.. (2015). The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers. Molecular Cancer Therapeutics. 14(3). 692–703. 141 indexed citations
11.
Verheijden, Gijs, Patrick H. Beusker, Ruud Ubink, et al.. (2015). Abstract P4-15-14: Preclinical data of SYD985 support the clinical investigation of this novel anti-HER2 antibody-drug conjugate in breast cancer patients with low levels of HER2 expression. Cancer Research. 75(9_Supplement). P4–15. 1 indexed citations
12.
Ubink, Ruud, Daniëlle C.H. Jacobs, Diels van den Dobbelsteen, et al.. (2014). Abstract 2651: Impressive efficacy and safety profile of a novel generation duocarmycin-based HER2-targeting ADC. Cancer Research. 74(19_Supplement). 2651–2651. 1 indexed citations
13.
Voermans, Nicol C., Kiek Verrijp, David Egging, et al.. (2011). Mild Muscular Features in Tenascin-X Knockout Mice, A Model of Ehlers–Danlos Syndrome. Connective Tissue Research. 52(5). 422–432. 24 indexed citations
14.
Egging, David, Ji-Won Choi, A. C. T. M. Peeters, et al.. (2008). Analysis of obstetric complications and uterine connective tissue in tenascin-X-deficient humans and mice. Cell and Tissue Research. 332(3). 523–532. 21 indexed citations
15.
Egging, David, et al.. (2007). Wound Healing in Tenascin-X Deficient Mice Suggests that Tenascin-X is Involved in Matrix Maturation Rather than Matrix Deposition. Connective Tissue Research. 48(2). 93–98. 46 indexed citations
16.
Egging, David, A. C. T. M. Peeters, Nicolaï Grebenchtchikov, et al.. (2007). Identification and characterization of multiple species of tenascin‐X in human serum. FEBS Journal. 274(5). 1280–1289. 13 indexed citations
17.
Egging, David, et al.. (2006). Interactions of human tenascin-X domains with dermal extracellular matrix molecules. Archives of Dermatological Research. 298(8). 389–396. 49 indexed citations
18.
Egging, David, et al.. (2005). Dermal connective tissue development in mice: an essential role for tenascin-X. Cell and Tissue Research. 323(3). 465–474. 25 indexed citations
19.
Bristow, James, William A. Carey, David Egging, & Joost Schalkwijk. (2005). Tenascin‐X, collagen, elastin, and the Ehlers–Danlos syndrome. American Journal of Medical Genetics Part C Seminars in Medical Genetics. 139C(1). 24–30. 76 indexed citations
20.
Peeters, A. C. T. M., Jean‐Pierre Timmermans, Franchette W.P.J. van den Berkmortel, et al.. (2004). A clinical and cardiovascular survey of Ehlers-Danlos syndrome patients with complete deficiency of tenascin-X.. PubMed. 62(5). 160–2. 18 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fiorella Petronzelli Breakdown of academic impact, for papers by M. I. Colnaghi Breakdown of academic impact, for papers by Heli Valtanen Breakdown of academic impact, for papers by Laurence Maggiorella Breakdown of academic impact, for papers by Bernard M. Tijink Breakdown of academic impact, for papers by Camilla Fröhlich Breakdown of academic impact, for papers by Merel Gijsen Breakdown of academic impact, for papers by Hidekazu Segawa Breakdown of academic impact, for papers by E. Kutarska Breakdown of academic impact, for papers by FO Smith
Rankless by CCL
2026